Actively Recruiting
Blood Biomarkers for Screening of Alzheimer's Disease
Led by Peking University First Hospital · Updated on 2024-06-27
180
Participants Needed
1
Research Sites
92 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this observational study is to estimate the screen performance of blood biomarkers of interest (Aβ40 and Aβ42, P-Tau181, P-Tau217, GFAP and NfL) in patients with Alzheimer's disease (AD), mild cognitive impairment due to AD, and cognitively normal individuals. The main questions it aims to answer are: * to identify core blood biomarker suitable for early screening of AD. * to establish a comprehensive model for the early identification of AD.
CONDITIONS
Official Title
Blood Biomarkers for Screening of Alzheimer's Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 64 50 years
- Diagnosed with Alzheimer's disease (meeting 2011 NIA-AA criteria), mild cognitive impairment (meeting 2004 Peterson criteria), or cognitively normal
- Signed informed consent form
You will not qualify if you...
- Presence of other disorders that can cause cognitive impairment
- Unable to cooperate with cognitive assessment
- Refusal to have blood drawn
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University First Hospital
Beijing, Beijing Municipality, China, 100034
Actively Recruiting
Research Team
C
Chen Zhang
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here